We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
MRK, Daiichi Begin Phase III Breast Cancer Study With ADC Candidate
Read MoreHide Full Article
Key Takeaways
MRK and Daiichi start dosing in a phase III study of HER3-DXd in HR-positive, HER2-negative breast cancer.
The study follows early data where HER3-DXd showed promising responses in metastatic breast cancer.
Primary endpoints include progression-free and overall survival, with safety as a secondary measure.
Merck (MRK - Free Report) and Japan’s Daiichi Sankyo announced the dosing of the first patient in the phase III HERTHENA-Breast04 study evaluating their investigational HER3-directed DXd antibody-drug conjugate (ADC), patritumab deruxtecan (HER3-DXd), for treating certain patients with breast cancer.
The open-label, randomized HERTHENA-Breast04 study will evaluate HER3-DXd versus an investigator’s choice of treatment in patients with unresectable locally advanced or metastatic hormone receptor (HR) positive, HER2 negative breast cancer whose disease progressed following endocrine and CDK4/6 inhibitor therapy in either adjuvant or first-line metastatic settings.
The initiation of the HERTHENA-Breast04 study is based on data from ICARUS-Breast01 and a phase I/II breast cancer study in which HER3-DXd demonstrated promising responses in patients with metastatic breast cancer.
The primary endpoint of the HERTHENA-Breast04 study will be progression-free survival by blinded independent central review and overall survival. The secondary endpoints of the study include objective response rate, duration of response and safety.
MRK's Price Performance
Year to date, shares of Merck have plunged 15.4% compared with the industry’s decline of 0.6%.
Image Source: Zacks Investment Research
MRK & Daiichi's Deal for HER3-DXd & Other ADC Candidates
Merck and Daiichi’s global clinical program is advancing HER3-DXd as a potential treatment across various cancer indications, including combination studies with other anticancer medicines.
Besides HER3-DXd, Merck acquired global co-development and co-commercialization rights to two other ADCs, ifinatamab deruxtecan and raludotatug deruxtecan, from Daiichi Sankyo in October 2023 for a total potential consideration of up to $22 billion. However, Daiichi Sankyo has retained exclusive rights for the development of the candidates in Japan.
In August last year, Merck expanded the collaboration to co-develop and co-commercialize MK-6070, an investigational T-cell engager targeting delta-like ligand 3 (DLL3), which it obtained from its recent acquisition of Harpoon Therapeutics.
Ifinatamab deruxtecan is being developed in separate phase III studies for treating small cell lung cancer, esophageal cancer and prostate cancer. The ADC candidate is also being evaluated both as monotherapy and in combination with other therapies in several early-to-mid-stage studies for treating various other solid tumors, including extensive-stage small cell lung cancer.
Raludotatug deruxtecan is being developed in various mid-stage studies for ovarian cancer as well as other cancer indications.
MRK’s Competition in the ADC Space
ADCs are being considered a disruptive innovation in the pharmaceutical industry, as these will enable better treatment of cancer by harnessing the targeting power of antibodies to deliver cytotoxic molecule drugs to tumors.
Daiichi Sankyo has several ADCs in clinical development across multiple types of cancer. It markets Enhertu, a HER2-directed ADC, in partnership with AstraZeneca (AZN - Free Report) , which is presently approved across multiple indications, including HER2-mutated breast, lung and gastric cancers.
In January 2025, the FDA approved AZN and Daiichi’s second ADC drug, Datroway, for treating unresectable or metastatic HR-positive, HER2-negative breast cancer in adult patients who have received prior endocrine-based therapy and chemotherapy. The FDA approved Datroway for its second indication, non-small-cell lung cancer, in June.
Pfizer (PFE - Free Report) also forayed into the lucrative ADC space with the acquisition of Seagen for $43 billion in late 2023.
Following this acquisition, PFE added three ADCs to its portfolio — Adcetris, Padcev, Tukysa and Tivdak — all approved across various types of solid tumors and hematologic malignancies. These products contributed meaningfully to Pfizer’s revenues in 2024 and in the first half of 2025.
Image: Shutterstock
MRK, Daiichi Begin Phase III Breast Cancer Study With ADC Candidate
Key Takeaways
Merck (MRK - Free Report) and Japan’s Daiichi Sankyo announced the dosing of the first patient in the phase III HERTHENA-Breast04 study evaluating their investigational HER3-directed DXd antibody-drug conjugate (ADC), patritumab deruxtecan (HER3-DXd), for treating certain patients with breast cancer.
The open-label, randomized HERTHENA-Breast04 study will evaluate HER3-DXd versus an investigator’s choice of treatment in patients with unresectable locally advanced or metastatic hormone receptor (HR) positive, HER2 negative breast cancer whose disease progressed following endocrine and CDK4/6 inhibitor therapy in either adjuvant or first-line metastatic settings.
The initiation of the HERTHENA-Breast04 study is based on data from ICARUS-Breast01 and a phase I/II breast cancer study in which HER3-DXd demonstrated promising responses in patients with metastatic breast cancer.
The primary endpoint of the HERTHENA-Breast04 study will be progression-free survival by blinded independent central review and overall survival. The secondary endpoints of the study include objective response rate, duration of response and safety.
MRK's Price Performance
Year to date, shares of Merck have plunged 15.4% compared with the industry’s decline of 0.6%.
Image Source: Zacks Investment Research
MRK & Daiichi's Deal for HER3-DXd & Other ADC Candidates
Merck and Daiichi’s global clinical program is advancing HER3-DXd as a potential treatment across various cancer indications, including combination studies with other anticancer medicines.
Besides HER3-DXd, Merck acquired global co-development and co-commercialization rights to two other ADCs, ifinatamab deruxtecan and raludotatug deruxtecan, from Daiichi Sankyo in October 2023 for a total potential consideration of up to $22 billion. However, Daiichi Sankyo has retained exclusive rights for the development of the candidates in Japan.
In August last year, Merck expanded the collaboration to co-develop and co-commercialize MK-6070, an investigational T-cell engager targeting delta-like ligand 3 (DLL3), which it obtained from its recent acquisition of Harpoon Therapeutics.
Ifinatamab deruxtecan is being developed in separate phase III studies for treating small cell lung cancer, esophageal cancer and prostate cancer. The ADC candidate is also being evaluated both as monotherapy and in combination with other therapies in several early-to-mid-stage studies for treating various other solid tumors, including extensive-stage small cell lung cancer.
Raludotatug deruxtecan is being developed in various mid-stage studies for ovarian cancer as well as other cancer indications.
MRK’s Competition in the ADC Space
ADCs are being considered a disruptive innovation in the pharmaceutical industry, as these will enable better treatment of cancer by harnessing the targeting power of antibodies to deliver cytotoxic molecule drugs to tumors.
Daiichi Sankyo has several ADCs in clinical development across multiple types of cancer. It markets Enhertu, a HER2-directed ADC, in partnership with AstraZeneca (AZN - Free Report) , which is presently approved across multiple indications, including HER2-mutated breast, lung and gastric cancers.
In January 2025, the FDA approved AZN and Daiichi’s second ADC drug, Datroway, for treating unresectable or metastatic HR-positive, HER2-negative breast cancer in adult patients who have received prior endocrine-based therapy and chemotherapy. The FDA approved Datroway for its second indication, non-small-cell lung cancer, in June.
Pfizer (PFE - Free Report) also forayed into the lucrative ADC space with the acquisition of Seagen for $43 billion in late 2023.
Following this acquisition, PFE added three ADCs to its portfolio — Adcetris, Padcev, Tukysa and Tivdak — all approved across various types of solid tumors and hematologic malignancies. These products contributed meaningfully to Pfizer’s revenues in 2024 and in the first half of 2025.
MRK's Zacks Rank
Merck currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.